MBC Advocate· @MBCadvocate · X·· 1 天前评分70
正文 · 机器翻译
在既往 CDK4/6i 和内分泌治疗后出现疾病进展的情况下，总生存期结果有利于 abemaciclib 加 fulvestrant。mOS 数值上更优，为 32个月 vs 25个月。更新后的 PFS、PFS2 和无化疗生存期均有利于 abemaciclib 加 fulvestrant。$AZN $LLY #ESMO26 https://mededgemea.com/new-cancer-treatment-data-to-be-presented-at-esmo-congress-2026/
51 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
1RO按 Rapid oral 1: Breast cancer, advanced stage 对上
Overall survival from the phase 3 postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor + endocrine therapy
https://esmocongress.esmo.orgAssociation of p27 V109G SNP zygosity with outcomes and abemaciclib treatment effect in HR+, HER2– high-risk early breast cancer: Results from monarchE
https://esmocongress.esmo.org来源：MBC Advocate · x.com